Predictors of cognitive function in pediatric brain tumor patients: Pre-surgery through 24-month follow-up. Issue 4 (2nd October 2021)

• Record Type: Journal Article
• Authors: Fraley, Claire E.; Thigpen, Jennifer C.; Pearson, Matthew M.; Kuttesch, John F.; Desjardins, Leandra; Hoskinson, Kristen R.; Alvarado-Gonzalez, Abraham; Esbenshade, Adam J.; Pastakia, Devang; Friedman, Debra L.; Wellons, John C.; McNally, Colleen M.; Siciliano, Rachel E.; Compas, Bruce E.
• Is Part Of: Applied neuropsychology. Volume 10:Issue 4(2021)
• Page Start: 340
• Page End: 347
• Publication Date: 2021-10-02
• Subjects: Cancer -- longitudinal assessment -- medical predictors -- oncology -- risk factors; Pediatric neuropsychology -- Periodicals; Neuropsychology -- Periodicals; Brain -- Physiology -- Periodicals; Brain -- Imaging -- Periodicals; Nervous system -- Diseases -- Diagnosis -- Periodicals; Nervous system -- Diseases -- Treatment -- Periodicals; 618.928
• DOI: 10.1080/21622965.2019.1706179
• Languages: English
• ISSNs: 2162-2965

Abstract

Abstract: The aim of this study was to examine the feasibility of cognitive assessment from pre-surgery through 2-year follow-up in a sample of pediatric brain tumor (BT) patients. We sought to investigate cognitive function over the course of diagnosis and treatment, and as a function of presenting problems, tumor location, treatment type, and tumor severity. Using a prospective, longitudinal design, standardized IQ measures were administered to pediatric BT patients (ages 6–16) prior to surgery ( n = 25), 6 months post-diagnosis ( n = 24), and 24 months post-diagnosis ( n = 23). Group differences emerged based on tumor severity and treatment type at multiple time points, including prior to surgical intervention; children with high grade tumors performed more poorly than children with low grade tumors, and children receiving surgery plus adjuvant therapy performed more poorly than children who received surgery only. When considered together, an analysis of covariance demonstrated that tumor grade significantly accounted for variability in cognitive functioning, while treatment type did not. Although there is overlap clinically between tumor severity and treatment received, results suggest that tumor severity is an important factor contributing to variability in cognitive functioning and should also be considered when monitoring risk for cognitive deficits in children diagnosed with BT.